Showing 61 - 80 results of 146 for search '"I Change"', query time: 0.14s Refine Results
  1. 61
  2. 62

    Optical band gap modulation in functionalized chitosan biopolymer hybrids using absorption and derivative spectrum fitting methods: A spectroscopic analysis by Dyari M. Mamand, Dana S. Muhammad, Daron Q. Muheddin, Karzan A. Abdalkarim, Dana A. Tahir, Hawkar A. Muhammad, Shujahadeen B. Aziz, Sarkawt A. Hussen, Jamal Hassan

    Published 2025-01-01
    “…The Lorentz-Drude model was used to derive several significant optical parameters, and the W-D model was utilized to calculate the optical moments M -1 changing from 0.35 to 2.13 and M -3 changing from 0.005 to 0.4. …”
    Get full text
    Article
  3. 63

    Efficacy of Chinese traditional quadruple single pill combination versus valsartan/hydrochlorothiazide for the treatment of hypertension (COSPQ-BP): study protocol for randomised c... by Kai Liu, Yu Yan, Xin Zhang, Yanan Li, Yuanyuan Yao, Lu Liu, Runyu Ye, Si Wang, Xiangyu Yang, Xiaoping Chen, Shanshan Jia, Qingtao Meng, Xianghao Zuo

    Published 2025-02-01
    “…The secondary outcomes have been predetermined and will primarily encompass the following: (1) changes in other BP measures, as well as changes in blood lipids, blood glucose and uric acid at 12 weeks and (2) evaluation of the impact of starting antihypertensive therapy with compound reserpine and triamterene tablets or valsartan/hydrochlorothiazide on the depressive and anxiety statess of patients.Ethics and dissemination The study protocol (version number: V5.0, version date: 17 January 2023) has been approved by the ethics committee (Biomedical Ethics Committee of West China Hospital of Sichuan University, approval number: Review (51) in 2023). …”
    Get full text
    Article
  4. 64
  5. 65
  6. 66
  7. 67
  8. 68
  9. 69
  10. 70
  11. 71
  12. 72
  13. 73
  14. 74
  15. 75
  16. 76
  17. 77
  18. 78
  19. 79
  20. 80

    Biologic Therapies for Chronic Obstructive Pulmonary Disease: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials by Tyler Pitre, Daniel Lupas, Jasmine Mah, Matthew Stanbrook, Alina Blazer, Dena Zeraatkar, Terence Ho

    Published 2025-01-01
    “…Outcomes of interest included exacerbations, change in FEV1, change in quality of life, and serious adverse events.Results Dupilumab reduced exacerbations as compared to placebo (RR 0.68 [95% CI 0.59 to 0.79]) (high certainty). …”
    Get full text
    Article